Biomarkers Profile in Provoked Versus Unprovoked Deep Venous Thrombosis

• Published in: Clinical and applied thrombosis/hemostasis 2024-01, Vol.30, p.10760296241238211-10760296241238211
• Main Authors: Tavares, Isabela Rodrigues, Caffaro, Roberto Augusto, Portugal, Maria Fernanda, Ribeiro, Camilla Moreira, da Silva, Viviane Santana, Krupa, Emily, Nikolovski, Srdjan, de Britto, Karen Falcão, Gomes Pereira Petisco, Ana Cláudia, Miranda, Maria Cristina, Gomes de Souza Santos, Sandra, da Silva Dourado, Marcela, Siqueira, Paula Veloso, Siddiqui, Fakiha, Fareed, Jawed, Ramacciotti, Eduardo
• Format: Article
• Language: English
• Subjects: Anticoagulants - therapeutic use; Biomarkers; Humans; Original; Prospective Studies; Pulmonary Embolism - drug therapy; Recurrence; Risk Factors; Venous Thromboembolism - drug therapy; Venous Thrombosis
• ISSN: 1076-0296; 1938-2723
• DOI: 10.1177/10760296241238211

Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), represents a substantial healthcare challenge. Provoked and unprovoked DVT cases carry distinct risks and treatment considerations. Recognizing the limitations of this classification, molecular markers may enhance diagnostic precision and guide anticoagulation therapy duration relying on patient history and risk factors. This preliminary, open-label, prospective cohort study was conducted including 15 patients (10 provoked DVT and 5 unprovoked DVT) and a control group of healthy plasmatic subjects. Plasma levels of 9 biomarkers were measured at diagnosis (baseline, day 0, and D0) and after 30 days (day 30-D30). Patient demographics, clinical data, and biomarker concentrations were analyzed. Serum concentrations of D-dimer, von Willebrand factor, C-reactive protein, and Anti-Xa were elevated in DVT groups at D0 compared to controls. No significant differences were observed between the provoked and unprovoked groups on the day of diagnosis and 30 days later. Over 30 days, the provoked group exhibited significant biomarker changes related to temporal assessment. No significant differences were noted in the biomarker profile between provoked and unprovoked DVT groups. This study is indicative of the concept of individualized thrombosis assessment and subsequent treatment for VTE. Larger cohorts are warranted to validate these findings and further define the most appropriate use of the molecular markers.